Skip to main content

New story in Health from Time: Johnson & Johnson Ending Sales of Talcum Powder Products in U.S.



Johnson & Johnson discontinued its legacy talc-based baby-powder products in the U.S. and Canada after thousands of suits alleging asbestos contamination led to a decline in sales.

The health-care giant said Tuesday it had stopped shipping hundreds of talc-based items in the U.S. and Canada after coming to a “commercial decision” to discontinue them. J&J will wind down sales in those markets over the coming months, said Kathleen Widmer, chairman of the company’s North America consumer unit. All existing inventory will continue to be sold through retailers until supplies run out, she said. J&J first began selling baby-powder products in the 1890s, according to a company blog.

J&J has faced lawsuits accusing it of hiding the cancer risks tied its talc-based version of baby powder since 2014. Juries across the U.S. have hit the company with billions of dollars in actual and punishment damages over their handling of the product. J&J has been successful in getting many of those verdicts reduced or wiped out on appeal.

Shares of the New Brunswick, New Jersey-based company declined 0.3% in late trading to $148.55. Since the start of this year, the shares had gained 2.2% through Tuesday’s close.

Read more: Johnson & Johnson Is Just the Tip of the Toxic Iceberg

J&J’s cornstarch-based baby powder, which has been on the market since 1980, will continue to be sold in the U.S. and Canada. Widmer said 75% of its U.S. baby-power customers use the cornstach product, while 25% rely on the talc-based product. Outside the U.S. those numbers are reversed, Widmer said, and the talc-based product will continue to be distributed abroad.

Johnson’s Baby Powder currently accounts for less than 1% of the company’s U.S. consumer-health revenue. It has seen a 60% decline in sales since 2017 as consumer habits have changed, Widmer said. The company blames “misinformation around the safety of the product and a constant barrage of litigation advertising” for the drop in demand, according to a statement.

“We’re not in the business of confusing customers,” Widmer said.

The decision to discontinue was made during a portfolio assessment related to Covid-19 in March.

“We needed to skinny down” to free up space in manufacturing plants to allow for appropriate social distancing, Widmer said. “We probably would have waited a couple of months otherwise. But we knew the business, which is already small in scale, would continue to decline.”

Talcum powder has long been a mainstay of baby products because the mineral keeps skin dry and prevents diaper rash. Talc mines, however, can also yield asbestos, a mineral once used in products such as building insulation. Some companies have found corn starch can offer the same benefits of talc without the asbestos risk.

In October, J&J said it would pull a single lot of 33,000 bottles off the market after a Food and Drug Administration-conducted test uncovered tiny amounts of the contaminant in one bottle of baby powder. But the company said lab tests it commissioned found no sign of asbestos in the recalled lot, putting it at odds with U.S. health regulators who stuck by their test results.

The standoff occurred as lawsuits against the company continued to climb. J&J officials said last month they’d had a 15% increase in the number of suits alleging baby powder causes different kinds of cancer. Discontinuing its talc-based baby powder in the U.S. could limit the number of cancer lawsuits the 127-year-old product generates each year.

J&J is likely seeking an “end date for talc claims,” said Leigh O’Dell, an Alabama-based lawyer who is overseeing more than 16,000 suits in federal court in New Jersey blaming the product for causing ovarian cancer. The move to discontinue sales “puts a fence around the litigation for them.”

Last year, Bausch Health Cos., maker of Shower to Shower powder, said it reformulated the product to replace talc with corn starch as the active ingredient. The firm hadn’t disclosed the switch until Bloomberg News asked about it.

J&J previously owned Shower to Shower but sold it to Bausch predecessor Valeant Pharmaceuticals International.

Johnson & Johnson “remains steadfastly confident in the safety of talc-based Johnson’s Baby Powder,” the company said in a statement. “We will continue to vigorously defend the product, its safety, and the unfounded allegations against it and the company in the courtroom.”

Labels:

Popular posts from this blog

New story in Health from Time: COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?

While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even with the ridership limits in place, Williams, 34, doesn’t feel safe on public transit. Some passengers don’t wear face coverings, and bus drivers sometimes ignore capacity limits, she says. On one ride with her seven-year-old son, she decided to get off at a stop far from her home after a driver allowed a crowd of people to board. “It’s very trying. I’ll put...
Read more

New story in Health from Time: An At-Home Coronavirus Test May Be On the Way in the U.S.

As cases of COVID-19 continue to climb in the U.S. , there’s a new urgency to make sure there are as many tests as possible to diagnose people who have symptoms that might indicate an infection. Knowing if people are positive is important for guiding their next steps: self-isolation, avoiding contact with others, and, if their symptoms get worse, seeking medical care. To date, access to tests has been spotty at best across the country, and while more kits are now available than even a week ago , most are gene-based assays that take several days for commercial labs to process and produce results. That may change in about two months if the Food and Drug Administration (FDA) gives Emergency Use Authorization to the first blood-based COVID-19 test in the U.S. Scanwell Health, an at-home test company based in California, licensed the rights to a test developed by Chinese company Innovita, which was used extensively at the height of country’s epidemic earlier this year. “The ...
Read more

New story in Health from Time: A Montana Care Home Refused Free COVID-19 Tests. Now, Nearly Every Resident Has Coronavirus

(BILLINGS, Mont.) — It was meant to be a last line of defense to protect the most vulnerable as the coronavirus spread across the United States : Montana officials offered free testing in May for staff and residents at assisted living and long-term care facilities. But not all of them followed through, according to state data, including a facility in Billings, Montana’s largest city, that cares for people with dementia and other memory problems. The virus has infected almost every resident and killed eight, accounting for almost a quarter of Montana’s 34 confirmed deaths. Thirty-six employees also have tested positive at the facility where 59 people lived before the deaths began. Read more: ‘It’s Getting Worse.’ Nursing Home Workers Confront Risks in Facilities Devastated by Coronavirus While Montana’s rates of confirmed infections and deaths are much lower than other parts of the country, the outbreak at Canyon Creek Memory Care illustrates that even the most simple an...
Read more